Abstract
Purpose: AL amyloidosis (AL) treatments are generally based on manageable grade 3 cytokine release syndrome evident in 2 patients those employed for multiple myeloma. Anti–B-cell maturation antigen and no neurotoxicity in any. Cardiac decompensations, observed in (BCMA) chimeric antigen receptor T (CART)-cell therapy, already ap-2 patients, were also short and manageable. The overall hematologic proved for multiple myeloma, might be too toxic for patients with AL. response and complete response rates were observed in all patients Experimental Design: Here we describe the ex vivo applicability of a with an organ response evident in all four. Within a median follow-novel in-house, academic anti-BCMA CAR construct on AL primary up period of 5.2 (2.5–9.5) months, all 4 patients maintained their cells, as well as the safety and efficacy in 4 patients with relapsed/refracresponses. tory (RR) primary AL, treated in a phase I clinical trial (NCT04720313). Conclusions: BCMA-CART cells provide a first proof-of-concept Results: Three had MAYO stage IIIa cardiac involvement at that this therapy is safe enough and highly efficacious for the enrollment. The treatment proved relatively safe, with a short and treatment of patients with advanced, RR AL.
Original language | English |
---|---|
Pages (from-to) | 5156-5166 |
Number of pages | 11 |
Journal | Clinical Cancer Research |
Volume | 28 |
Issue number | 23 |
DOIs | |
State | Published - 1 Dec 2022 |
Bibliographical note
Publisher Copyright:©2022 American Association for Cancer Research.
Funding
This work is supported by generous support from Steinfeld and Cuniff family, the estate of Allan Habelson, and by the Amyloidosis Patient Association of Israel. C.J. Cohen is supported by the Adelis Foundation and the Israel Science Foundation (646/20).
Funders | Funder number |
---|---|
Amyloidosis Patient Association of Israel | |
Achelis Foundation | |
Israel Science Foundation | 646/20 |